Jacobs Bruce N. 4
4 · Kymera Therapeutics, Inc. · Filed Jan 13, 2025
Insider Transaction Report
Form 4
Jacobs Bruce N.
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2025-01-10$2.08/sh+10,000$20,800→ 178,921 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-01-10−10,000→ 94,899 totalExercise: $2.08Exp: 2029-08-28→ Common Stock (10,000 underlying)
Footnotes (2)
- [F1]This number includes 367 shares acquired under the Registrant's employee stock purchase plan on December 1, 2024
- [F2]Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares vested in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.